NCT05201781 2026-03-17
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Janssen Research & Development, LLC
Phase 4 Recruiting
Clinical Trials
10 trialsNCT07474961 2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4 Not yet recruiting
NCT07030517 2026-03-13
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
Johnson & Johnson Private Limited
Phase 4 Recruiting
NCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
NCT07101445 2026-02-10
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Emory University
Phase 4 Recruiting
NCT06057402 2026-01-27
MagnetisMM15
Pfizer
Phase 4 Recruiting
NCT07334535 2026-01-13
Isa-VRD in TIE HRMM
Peking Union Medical College Hospital
Phase 4 Not yet recruiting
NCT07094048 2026-01-07
CHUQUL_HO001
CHU de Quebec-Universite Laval
Phase 4 Recruiting
NCT05722405 2026-01-05
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4 Recruiting
NCT04952766 2025-12-23
EREVA
Centre Hospitalier Régional d'Orléans
Phase 4 Completed